FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Report a Drug Shortage | Contact Us | FAQ | Background Info | Get Email Alerts | Download Current Drug Shortages

Start Over | Back to Previous Screen

Diltiazem Hydrochloride Injection
Status: Currently in Shortage
»Date first posted: 02/21/2018
»Therapeutic Categories: Cardiovascular

Expand all

Akorn Pharmaceuticals (Revised 06/06/2023)

Company Contact Information:
800-932-5676

Presentation	Availability and Estimated Shortage Duration	Related Information	Shortage Reason (per FDASIA)
Diltiazem HCl Injection 5 mg / mL, 10 mL, 10 vials (NDC 17478-937-10)	Not available	No new manufacturing of product
Diltiazem HCl Injection 5 mg / mL, 25 mL, 1 vial (NDC 17478-937-25)	Not available	No new manufacturing of product
Diltiazem HCl Injection 5 mg / mL, 25 mL, 10 vials (NDC 17478-937-26)	Not available	No new manufacturing of product
Diltiazem HCl Injection 5 mg / mL, 5 mL, 10 vials (NDC 17478-937-05)	Not available	No new manufacturing of product

Athenex Pharmaceutical Division, LLC (Athenex) (Reverified 05/09/2023)

Company Contact Information:
855-273-0154

Presentation	Availability and Estimated Shortage Duration	Related Information	Shortage Reason (per FDASIA)
25 mg/5mL vial (NDC 70860-301-05)	On backorder.	Next shipment TBD
50 mg/10mL vial (NDC 70860-301-10)	On backorder.	Next shipment TBD
125 mg/25mL vial (NDC 70860-301-25)	On backorder.	Next shipment TBD

Hikma Pharmaceuticals USA, Inc. (formerly West-Ward) (Revised 05/16/2023)

Company Contact Information:
800-631-2174

Presentation	Availability and Estimated Shortage Duration	Related Information	Shortage Reason (per FDASIA)
5 mg/mL, 5 mL vial (NDC 0641-6013-10)	This presentation is temporarily on backorder.	Additional lots will be scheduled for manufacturing and will be available in the May - June 2023 timeframe. Product will be made available as it is released.	Demand increase for the drug
5 mg/mL, 10 mL vial (NDC 0641-6014-10)	Inventory is currently available	Additional lots are scheduled for manufacturing to meet demand. Product will be made available as it is released.	Demand increase for the drug
5 mg/mL, 30 mL vial (NDC 0641-6015-10)	This presentation is temporarily on backorder.	Additional lots will be scheduled for manufacturing and will be available in the June 2023 timeframe. Product will be made available as it is released.	Demand increase for the drug

Hospira, Inc. (Revised 06/07/2023)

Company Contact Information:
844-646-4398

Presentation	Availability and Estimated Shortage Duration	Related Information	Shortage Reason (per FDASIA)
100 mg; Single Dose ADD-Vantage Vial (NDC 0409-4350-03)	Available		Other